Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02

BACKGROUND: Vorinostat, a histone deacetylase (HDAC) inhibitor, has shown radiosensitizing properties in preclinical studies. This open-label, single-arm trial evaluated the maximum tolerated dose (MTD; phase I) and efficacy (phase II) of vorinostat combined with standard chemoradiation in newly dia...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Galanis, Evanthia, Anderson, S Keith, Miller, C Ryan, Sarkaria, Jann N, Jaeckle, Kurt, Buckner, Jan C, Ligon, Keith L, Ballman, Karla V, Moore, Dennis F, Nebozhyn, Michael, Loboda, Andrey, Schiff, David, Ahluwalia, Manmeet Singh, Lee, Eudocia Q, Gerstner, Elizabeth R, Lesser, Glenn J, Prados, Michael, Grossman, Stuart A, Cerhan, Jane, Giannini, Caterina, Wen, Patrick Y
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Clinical Investigations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5909661/
https://ncbi.nlm.nih.gov/pubmed/29016887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox161
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars